The IOCB Tech Foundation has become the IOCB Foundation. With stronger ties to IOCB Prague, it aims to accelerate technology transfer, support innovation, and expand science philanthropy.

IOCB Prague hosted HIV prevention pioneers discussing lenacapavir, a long-acting drug that could shift HIV prevention from daily pills to a single yearly injection.

New androstane-based steroid derivatives can significantly improve antibiotic efficacy against multidrug-resistant Staphylococcus aureus, offering a promising strategy to overcome efflux-mediated resistance.

IOCB Prague researchers developed potent CD73 inhibitors that restore T cell activity and reduce adenosine, opening new paths for cancer immunotherapy.

Scientists at IOCB Prague reveal a previously unknown mechanism that initiates gene transcription. Using cryo-EM, they uncover how alarmone molecules enable RNA synthesis under stress.

Researchers at IOCB Prague have developed new fluorogenic labels that deliver high-contrast fluorescence microscopy, enabling precise visualization of cellular processes without background noise.

Structure-guided libraries and machine learning enable faster discovery of active nucleic acid sequences beyond random mutagenesis.

Alcohol consumption produces acetaldehyde, a toxic compound that damages DNA. Scientists from IOCB Prague reveal how cells repair this damage, shedding light on the link between alcohol and cancer.

IOCB Prague is co-founding Taveren Therapeutics, a new biotech spin-off developing a novel cancer treatment strategy based on reactivating the body’s natural tumor suppressors.

Researchers at IOCB Prague developed a highly precise and ultra-stable fluorescent labeling method that stays attached even inside cells, enabling long-term, reliable tracking of biomolecules.